BPC-157: what it is, how it is thought to work and what studies have found

BPC-157 is one of the most discussed peptides on the internet and one of the least tested in people. The molecule itself is simple: 15 amino acids, no modifications, a molecular weight a little over 1.4 kDa. The evidence around it is not. Of roughly 230 PubMed records on it, about three-quarters list one Zagreb researcher as an author, and most of the work is in rats, while the human record amounts to three small uncontrolled reports [4] [7].

This review sets out what is known, how strong each piece of evidence is, and where the molecule stands with regulators. It is written for researchers and quality teams. It does not give, and should not be read as, guidance on human use.

What is BPC-157?

BPC-157 (body protection compound 157) is a synthetic pentadecapeptide. In 1993, researchers at the University of Zagreb described a gastric juice protein of about 40 kDa that they named BPC, and a 15-amino-acid fragment of it, BPC 157, “thought to be essential for its activity” [1]. The same group framed it as an “organoprotective” agent within a stomach-stress hypothesis [1].

The peptide also appears in the literature as PL 14736, PL-10, PLD-116 and bepecin [2]. FDA notes that it is “reported to be comprised of 15 amino acids” and that BPC-157 is a common name rather than a United States Adopted Name, with naming that does not follow USAN, INN or IUPAC conventions [3].

Two facts frame everything that follows:

• The evidence is concentrated in one laboratory. Of 230 PubMed records that mention BPC-157 or PL 14736 in the title or abstract, 174 (76%) list Predrag Sikirić as an author [4]. A 2025 review also observed that “all the published studies report positive or beneficial effects of BPC-157” [5], a pattern that calls for independent replication.
• The evidence is overwhelmingly preclinical. A 2025 systematic review of musculoskeletal studies included 36 papers, of which 35 were preclinical and one was clinical [6]. A 2026 systematic review of human evidence found three studies with 30 participants in total and rated certainty of evidence as very low [7].

BPC-157 structure, sequence and molecular weight

Property	Value
Name	BPC-157 (body protection compound 157); also PL 14736, bepecin [2]
INN / USAN	None identified; FDA describes BPC-157 as a common name, not a USAN [3]
CAS number	137525-51-0 [2]
Sequence (one-letter)	GEPPPGKPADDAGLV [2]
Sequence (three-letter)	H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH [3]
Length	15 amino acids, linear, free N- and C-termini [3]
Molecular formula	C62H98N16O22 [2] [3]
Molecular weight	1419.5 g/mol (free base) [3]
Modifications	None; all L-amino acids [2]
Salt forms	Free base and acetate are treated by FDA as different drug substances; trifluoroacetate is also listed [2] [3]
Melting point	Above 232 °C (as cited by FDA) [3]

The sequence is unusually rich in proline (four of 15 residues, including a Pro-Pro-Pro run) and carries a net acidic character from one glutamate and two aspartates against a single lysine. The free base and the acetate salt differ in counter-ion content, so a certificate of analysis should state which form is supplied. FDA singled out exactly this ambiguity: neither 503A nomination made clear whether it meant BPC-157 acetate or free base [3].

BPC-157 mechanism of action: what has been proposed

No receptor for BPC-157 has been identified. FDA’s 2026 evaluation states that “the molecular targets for BPC-157-related substances have not been identified, and the mechanisms of action of BPC-157-related substances remain poorly understood” [3]. The mechanisms below are hypotheses drawn from cell and animal experiments.

Proposed pathway	Model	Evidence level	Reported finding	Ref
VEGFR2 up-regulation and VEGFR2-Akt-eNOS signalling	Chick chorioallantoic membrane; human vascular endothelial cells; rat hind-limb ischaemia	In vitro and animal	Increased vessel density and tube formation; increased VEGFR2 (not VEGF-A) expression; VEGFR2 internalisation blocked by dynasore	[8]
Src-caveolin-1-eNOS and nitric oxide	Isolated rat aorta; endothelial cells	Ex vivo and in vitro	Endothelium- and NO-dependent vasodilation; reduced caveolin-1/eNOS binding	[9]
FAK-paxillin activation	Rat Achilles tendon explants and fibroblasts	In vitro	Faster explant outgrowth, better survival under H2O2 stress, more migration; no direct effect on proliferation	[10]
Growth hormone receptor up-regulation	Rat tendon fibroblasts	In vitro	Dose- and time-dependent rise in GH receptor mRNA and protein; JAK2 activation when GH was added	[11]

In plain terms, the most reproduced theme is endothelial nitric oxide signalling and angiogenesis, reported by an independent group in Taiwan [8] [9] as well as by the Zagreb group [12]. A 2025 narrative review summarised the proposed picture as VEGFR2 and Akt-eNOS activity, ERK1/2 signalling and anti-inflammatory effects [5]. FDA cautions that dose-response relationships have not been established for the gastrointestinal and liver effects it reviewed, and that without identified molecular targets the biological plausibility of the reported effects is hard to assess [3].

Development history and timeline

Year	Event	Ref
1993	Zagreb group describes the gastric juice protein BPC and characterises the 15-residue fragment BPC 157	[1]
Early 1990s	First synthesised at the University of Zagreb by Fmoc solid-phase synthesis	[3]
2000s	Developed as PL 14736 with Pliva (Croatia) for inflammatory bowel disease; described by the group as “safe in clinical trials”	[12]
2005	Randomised enema trial in ulcerative colitis reported only as a meeting abstract (Ruenzi et al., as summarised by FDA)	[3]
2015	PCO-02 (oral BPC-157 tablets) phase 1 study in healthy volunteers registered by PharmaCotherapia d.o.o.; status unknown, no results posted	[13]
2021 to 2025	Three small uncontrolled human reports published by one lead author from private clinic settings	[14] [15] [16]
2022	WADA names BPC-157 under S0 non-approved substances	[5]
September 2023	FDA places BPC-157 in category 2 of its interim compounding policy	[5]
By April 2026	FDA’s category 2 page (content current as of 22 April 2026) lists BPC-157 among substances “nominated but withdrawn”, previously in category 2	[17]
May to July 2026	FDA evaluation (dated 11 May 2026) concludes the criteria weigh against the 503A bulks list; Pharmacy Compounding Advisory Committee meets on 23 July 2026	[3] [18]
23 July 2026	Committee members reportedly vote 8 to 6, with one abstention, in favour of adding BPC-157 to the compounding list; non-binding, no FDA final determination yet	[27]

Key BPC-157 studies and findings

The table separates the animal work from the human reports. Doses are not reproduced here.

Study	Design / evidence level	Model or population	n	Main finding	Ref
Staresinic 2003	Animal	Rats with transected Achilles tendon	Not stated in abstract	Higher load to failure, better functional index and histology than saline controls over 14 days	[19]
Hsieh 2017	In vitro and animal	Endothelial cells; rat hind-limb ischaemia	Not stated in abstract	Faster blood-flow recovery and more vessels; VEGFR2-Akt-eNOS activation	[8]
He 2022	Animal pharmacokinetics	Rats and beagle dogs	Not stated in abstract	Half-life of intact peptide under 30 min; IM bioavailability about 14-19% (rats) and 45-51% (dogs); urine and bile excretion	[20]
Ruenzi 2005 (abstract)	Randomised, double-blind, placebo-controlled	Mild to moderate ulcerative colitis	53	Mean disease activity change −3.2 vs −1.6; between-group difference not significant	[3]
Lee and Padgett 2021	Retrospective chart review, no control	Knee pain, primary care clinic	16	14 of 16 reported relief (four also received thymosin beta-4); outcome by phone survey, no validated tools	[14]
Lee et al. 2024	Uncontrolled pilot	Women with interstitial cystitis	12	10 of 12 reported complete symptom resolution; no adverse events reported	[15]
Lee and Burgess 2025	Uncontrolled pilot	Healthy adults	2	No measurable effect on tested blood markers; no side effects reported	[16]

Animal studies: broad, positive and mostly from one group

The animal literature covers gastric and intestinal lesions, fistulas, liver injury, tendon, ligament, muscle and bone. The 2025 musculoskeletal systematic review reported that, in preclinical models, BPC-157 “improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bony injuries” [6]. Rats were the most common species, with rabbits and dogs in a few studies [6].

A typical example is the 2003 Achilles tendon study: in rats with a transected tendon, treated animals showed higher load of failure, higher Young’s modulus and a smaller tendon defect than saline controls [19]. Results of this kind are consistent across many papers, but most come from the same laboratory, and the 2025 systematic review graded the body of evidence as level IV and V [6]. FDA added that dose-response relationships have not been established for the gastrointestinal and liver effects it reviewed [3].

An independent 2026 rat study from Türkiye compared BPC-157, TB-500 and the combination after Achilles tendon repair (n = 32, eight per group). BPC-157 improved histology numerically, but its total scores did not reach statistical significance, while the TB-500 group showed a significant biomechanical advantage [21]. The authors called the study exploratory [21].

The ulcerative colitis trials

BPC-157 was developed as PL 14736 for inflammatory bowel disease in the 2000s, and the Zagreb group described it as “safe in clinical trials” [12]. For ulcerative colitis, FDA identified a single efficacy report: a meeting abstract describing a randomised, double-blind trial of a rectal enema formulation versus placebo for two weeks in 53 patients with mild to moderate ulcerative colitis [3]. Mean disease activity index change was −3.2 with BPC-157 and −1.6 with placebo; the estimated difference had a confidence interval spanning zero [3]. FDA judged the data “inadequate to support the efficacy and safety” of the enema [3].

The three human reports

All three were published in the same journal by the same lead author, from private clinic settings (two of the abstracts place the work in Florida):

1. Knee pain (2021). A retrospective review of 17 patients, 16 of whom were reached by telephone. Of the 12 who received BPC-157 alone, 11 reported significant improvement; the other four also received thymosin beta-4, and overall 14 of 16 reported relief. No validated outcome tools were used [14].
2. Interstitial cystitis (2024). Twelve women who had not responded to pentosan polysulfate received BPC-157 injected around the inflamed area of the bladder during a single cystoscopy. Ten reported complete resolution of symptoms; no adverse events were reported. There was no control group [15].
3. Intravenous safety (2025). Two adults, both of whom had received intravenous BPC-157 before, were infused on two consecutive days. No measurable effects on heart, liver, kidney, thyroid or glucose markers were reported [16].

The 2026 systematic review judged all three to be of poor methodological quality and rated the overall certainty of evidence as very low “due to serious risk of bias, indirectness and imprecision” [7]. Its conclusion was that BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials” [7].

Registered trials

ClinicalTrials.gov lists a 2015 randomised phase 1 study of oral PCO-02 tablets in an estimated 42 healthy volunteers in Tijuana, Mexico; its status is unknown and no results have been posted [13]. A randomised phase 1 pilot after arthroscopic rotator cuff repair, sponsored by the University of Arkansas, was first posted in September 2026 with an estimated enrolment of 30 and is listed as not yet recruiting; the record is registered as quadruple-masked but describes its comparator inconsistently, as a no-treatment sham arm in one field and a saline placebo in another [22]. That record notes that BPC-157 “has not yet been studied in formal human clinical trials” [22].

BPC-157 half-life and pharmacokinetics

The only full pharmacokinetic study is in animals. In rats and beagle dogs, the elimination half-life of intact BPC-157 was under 30 minutes after intravenous or intramuscular dosing, with linear pharmacokinetics [20]. FDA’s review of the same study gives 5.3 minutes in dogs and 15.2 minutes in rats after a single intravenous dose [3]. Using tritium-labelled peptide, the authors showed rapid breakdown into small fragments and then single amino acids, excreted mainly in urine and bile [20].

BPC-157 was reported to resist hydrolysis in gastric juice in vitro, so FDA attributes its short in vivo half-life to blood and tissue peptidases [3]. FDA found no information to assess pharmacokinetics in humans [3].

Safety findings reported in studies

• Animal toxicology. FDA’s summary of the published studies reports no signs of acute toxicity or histopathological change 14 days after single intramuscular doses in rats and beagle dogs, and negative bacterial reverse mutation, chromosome aberration and mouse bone marrow micronucleus tests [3]. FDA judged the nonclinical studies “too limited in scope and duration” for the proposed routes [3].
• Human reports. None of the three pilot reports described treatment-related adverse events [14] [15] [16], but with 30 participants and no controls, absence of reported harm says little [7].
• Ulcerative colitis trial. Three patients on BPC-157 and two on placebo withdrew because of adverse events, mainly progression of colitis [3].
• Spontaneous reports. FDA’s adverse event database contains reports of injection site reaction, shortness of breath, and diffuse hyperpigmentation with gingival darkening; causality is unclear [3].
• Product quality and immunogenicity. FDA states that BPC-157 “may pose a significant risk for immunogenicity” by parenteral or nasal routes, “potentially amplified by aggregation as well as potential peptide-related impurities” [3]. It also notes that most certificates of analysis it found reported purity only [3].

The 2025 musculoskeletal systematic review found no clinical safety data and noted that adverse effects “are possible due to unregulated manufacturing, contamination, or unknown clinical safety” [6]. FDA likewise found insufficient information to support the safety of long-term use in patients with ulcerative colitis [3].

BPC-157 regulatory status by region

Region / body	Status	Ref
United States (FDA)	Not approved; not a component of any approved drug; no USP or NF monograph. Previously in category 2; now listed as nominated but withdrawn. FDA’s May 2026 evaluation concluded that a balancing of the criteria weighs against adding BPC-157 free base or acetate to the 503A bulks list; the July 2026 advisory committee reportedly voted 8 to 6 (one abstention) in favour; no final FDA determination yet	[3] [17] [27]
European Union	No approved product; not in the European Pharmacopoeia	[3]
Japan and international	Not in the Japanese or International Pharmacopoeias	[3]
Any country	”There is no approved product containing BPC-157-related BDSs in any country at this time” (FDA, 2026)	[3]
Sport (WADA)	Prohibited at all times, class S0 non-approved substances; retained on the 2027 list	[23] [24]

The FDA 503A review in 2026

Two nominations had asked FDA to add BPC-157 to the 503A bulks list, which would allow licensed pharmacies to compound with it. Both were withdrawn, but FDA chose to evaluate BPC-157 free base and acetate on its own initiative for ulcerative colitis [3] [25]. The evaluation concluded that “a balancing of the criteria weighs against” listing, because the substances are not well characterised, safety and immunogenicity data are lacking, effectiveness evidence is insufficient, and approved treatments for ulcerative colitis exist [3].

The Pharmacy Compounding Advisory Committee discussed BPC-157-related substances, for ulcerative colitis, on 23 July 2026 [25] [18]. ABC News reported that the committee voted 8 to 6, with one abstention, in favour of adding BPC-157 to the compounding list, and that the vote is non-binding and still needs FDA sign-off [27]. The vote ran counter to the conclusion of FDA’s own evaluation [3]. At the time of writing, FDA’s meeting page lists the briefing documents, agenda and presentations but no minutes or voting results, and FDA has said it will not issue a final determination until the advisory process is complete [25] [18]. A favourable vote would not make BPC-157 an approved drug, and it does not add to the clinical evidence described above.

Sport

The US Anti-Doping Agency states that BPC-157 is prohibited under the S0 non-approved substances class of the WADA list [23]. Its advisory on the 2027 list confirms “BPC-157 (Prohibited under S0)”, notes that peptides in general are now named in S0, and states that “S0 substances are prohibited at all times” [24].

BPC-157 in laboratory research

The published BPC-157 work uses a fairly standard toolkit, which makes it straightforward to design independent replication:

• Angiogenesis assays: chick chorioallantoic membrane, endothelial tube formation and VEGFR2 expression and internalisation in human vascular endothelial cells [8].
• Vascular function: isolated rat aortic rings with and without endothelium, L-NAME or haemoglobin to test NO dependence, and co-immunoprecipitation of caveolin-1 and eNOS [9].
• Tendon cell biology: tendon explant outgrowth, MTT proliferation, transwell migration, H2O2 survival and FAK and paxillin phosphorylation by Western blot [10]; cDNA microarray and growth hormone receptor expression [11].
• In vivo injury models: Achilles transection with biomechanical testing and functional index [19] [21]; hind-limb ischaemia with laser Doppler [8].
• Bioanalysis: radiolabelled tracer studies of distribution, metabolism and excretion in rats and dogs [20].

For characterisation, identity is normally confirmed by mass spectrometry against the theoretical mass of C62H98N16O22, with purity by reversed-phase HPLC. FDA’s point that most available certificates report only purity, without impurity limits, aggregates, bioburden or endotoxin, is a useful checklist for what a complete research-grade certificate should include [3]. Any replication study should state the salt form, counter-ion content and peptide content, since FDA treats free base and acetate as different substances [3].

Synthesis, purity and impurities

BPC-157 is made by chemical synthesis. In the original 1993 route, as summarised by FDA, Fmoc-protected amino acids were coupled stepwise on a polymeric benzhydrylamine resin with diisopropylcarbodiimide, Fmoc groups were removed with piperidine, the peptide was cleaved with a trifluoroacetic acid, trifluoromethanesulfonic acid and anisole mixture, and the crude product was purified by HPLC to more than 95% purity [3]. Later groups have also reported solid-phase routes [20]; the trade-offs between solid-phase and solution-phase routes are covered in SPPS vs LPPS.

FDA lists the impurity classes expected for a solid-phase peptide such as BPC-157 [3]:

• peptide-related impurities from incomplete couplings, truncations and side reactions, which are structurally close to the target and hard to resolve;
• impurities carried over from protected amino acid starting materials, including isomers and free amino acids;
• process residues: solvents, coupling reagents, activators, catalysts and scavengers;
• peptide aggregates, which FDA links to immunogenicity risk.

For a 15-residue peptide, a racemised residue does not change the mass at all and a single deletion may elute close to the main peak, so a stability-indicating HPLC method and LC-MS identification of the main related substances matter more than a single purity number. Specification setting is discussed in peptide API impurities and specifications.

Storage and stability of lyophilized BPC-157

FDA’s review cites literature reporting that BPC-157 free base “is expected to be stable under storage conditions below −18 °C” and the acetate below −20 °C [3]. It also notes that moisture “will greatly decrease long-term stability of lyophilized peptides” and that peptides are sensitive to pH, temperature, concentration and excipients, which can drive aggregation and degradation [3]. For laboratory stock, that means frozen storage in sealed, desiccated containers, equilibration to room temperature before opening, and minimal freeze-thaw cycling of solutions. General principles are in lyophilised peptide stability and storage.

BPC-157 vs TB-500

BPC-157 and TB-500 are often discussed together, but they are unrelated molecules.

	BPC-157	TB-500
Origin	Fragment of a gastric juice protein (BPC) [1]	Acetylated fragment 17-23 of thymosin beta-4 [26]
Sequence	GEPPPGKPADDAGLV [2]	Ac-LKKTETQ [26]
Length and mass	15 residues, 1419.5 g/mol [3]	7 residues, 889.01 g/mol (free base) [26]
Proposed biology	NO and VEGFR2 signalling, fibroblast migration [8] [10]	Actin-binding motif of thymosin beta-4 [26]
Human studies	Three small uncontrolled reports [7]	FDA found none of TB-500 itself [26]
FDA 2026 evaluation	Weighs against 503A listing [3]	Weighs against 503A listing [26]
WADA class	S0 [24]	S2 [24]

In the one study that compared them head to head, in rats after Achilles tendon repair, TB-500 alone produced a significant biomechanical gain, BPC-157 alone did not reach significance on total histology scores, and the combination gave no additional benefit over either peptide alone [21]. The distinction between TB-500 and full-length thymosin beta-4 is explained in TB-500: structure, mechanism and research findings.

How Winhycare Pharma supplies BPC-157

Winhycare Pharma supplies BPC-157 as research-use-only material for laboratories and as an active pharmaceutical ingredient to licensed manufacturers. Material is supplied at a purity of at least 99%, as stated in our brochure, with a certificate of analysis that states the salt form, and custom synthesis is available. Product details are on the BPC-157 page; to discuss API or research supply, contact our pharma team.

For laboratory research use only. Not for human or veterinary use.